Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|5|1755-1757

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.5, 2015-05, pp. : 1755-1757

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 10, 2015-10 ,pp. : E130-E140

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 534-545

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of pERK and VEGFR‐2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 8, 2015-08 ,pp. : 2001-2008

John Wiley & Sons Inc

Access to resources Recommend Favorite

MicroRNA‐425‐3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1077-1086

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antiviral therapy in the improvement of survival of patients with hepatitis B virus‐related hepatocellular carcinoma treated with sorafenib

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 6, 2015-06 ,pp. : 1032-1039

John Wiley & Sons Inc

Access to resources Recommend Favorite